ELUT Stock Overview
A commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Elutia Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.25 |
| 52 Week High | US$4.19 |
| 52 Week Low | US$1.10 |
| Beta | 0.56 |
| 1 Month Change | 10.92% |
| 3 Month Change | -11.44% |
| 1 Year Change | 41.92% |
| 3 Year Change | -71.62% |
| 5 Year Change | n/a |
| Change since IPO | -77.59% |
Recent News & Updates
Recent updates
News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
Mar 10
Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
Feb 21Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding
Apr 17Aziyo Biologics appoints Williams as Chief Scientific Officer
Aug 26Aziyo Biologics names co-founder C. Randal Mills as permanent CEO
Aug 10Shareholder Returns
| ELUT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | -0.6% |
| 1Y | 41.9% | 5.5% | 22.2% |
Return vs Industry: ELUT exceeded the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: ELUT exceeded the US Market which returned 22.2% over the past year.
Price Volatility
| ELUT volatility | |
|---|---|
| ELUT Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ELUT has not had significant price volatility in the past 3 months.
Volatility Over Time: ELUT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 54 | Randy Mills | elutia.com |
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women’s Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
Elutia Inc. Fundamentals Summary
| ELUT fundamental statistics | |
|---|---|
| Market cap | US$79.14m |
| Earnings (TTM) | -US$49.46m |
| Revenue (TTM) | US$25.05m |
3.2x
P/S Ratio-1.6x
P/E RatioIs ELUT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELUT income statement (TTM) | |
|---|---|
| Revenue | US$25.05m |
| Cost of Revenue | US$14.53m |
| Gross Profit | US$10.52m |
| Other Expenses | US$59.98m |
| Earnings | -US$49.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.03 |
| Gross Margin | 42.01% |
| Net Profit Margin | -197.48% |
| Debt/Equity Ratio | -43.8% |
How did ELUT perform over the long term?
See historical performance and comparison